Pharmacological inhibition of IL8 may represent a potential approach to improve existing therapeutic regimes for breast cancer patients with de novo or acquired resistance to anti-estrogen therapies and to prophylactically alleviate metastatic diseases. Here, CXCL8 is linked to breast carcinoma.